#AS­CO22: Ear­ly stock win­ner Adicet re­ports CRs for their off-the-shelf gam­ma delta CAR-T

Adicet is get­ting cen­ter-ring at­ten­tion to­day for its pos­i­tive cut of the ear­ly da­ta for their off-the-shelf gam­ma delta T cell play­er.

At the da­ta cut­off date of May 31, 6 of the 8 pa­tients en­rolled record­ed a com­plete re­sponse, net­ting a 75% re­sponse rate across three dif­fer­ent dosage lev­els. That’s like­ly to sharp­en the fo­cus on the gam­ma delta crowd — which is hop­ing to see en­hanced ef­fi­ca­cy — af­ter at­tract­ing con­sid­er­able in­ter­est from Take­da and oth­ers ac­tive in on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER